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Opioid growth factor inhibits intimal hyperplasia
in balloon-injured rat carotid artery
Ian S. Zagon, PhD,a Frank M. Essis, Jr, MS,a Michael F. Verderame, PhD,b Dean A. Healy, MD,c
Robert G. Atnip, MD,c and Patricia J. McLaughlin, DEd,a Hershey, Pa
Objective: The endogenous opioid [Met5]-enkephalin (opioid growth factor [OGF]) is a tonically active, receptor-
mediated inhibitory growth peptide in developing and adult vasculature. This study was designed to determine the role
of OGF in neointimal hyperplasia.
Methods: The carotid artery in adult male Sprague-Dawley rats was denuded with balloon catheterization. OGF (10
mg/kg), the opioid antagonist naltrexone (NTX; 30 mg/kg), or saline solution (0.2 mL) was injected intraperitoneally
daily for 28 days into the rats, and restenosis of the carotid artery was examined with morphometric analysis using
Optimas software. Proliferation of the neointima and media was measured by radioactive thymidine incorporation over
3 hours. The presence of OGF and its receptor, OGFr, were examined with immunofluorescence microscopy.
Results: OGF depressed DNA synthesis in the intima and media from 16% to 78% of control levels in the first 2 weeks after
deendothelialization, whereas NTX exposure elevated DNA synthesis by 21% to 89%. OGF action was receptor-mediated.
In the month after injury the thickness of the intima in OGF-treated rats was decreased by 18% to 31% from control
values, whereas intimal thickness was increased in the NTX group by 10% to 31%. Luminal area was almost 25% greater
than control values in the OGF group, but was reduced 17% by NTX. OGF and the OGF receptor were detected in the
carotid artery with immunohistochemistry.
Conclusions: These results demonstrate for the first time that a native opioid system modulates repair of vascular injury.
OGF is a constitutively active peptide that has a receptor-mediated action in the negative regulation of neointimal growth,
a major cause of restenosis. (J Vasc Surg 2003;37:636-43.)
The wall of arteries is a complex, multicellular structure
that is important in regulation of inflammation, coagula-
tion, and regional blood flow.1,2 Vascular smooth muscle
cells (SMC), mainly located in the tunica media of the
artery, are important modulators of vascular tone and
blood pressure in some blood vessels. Injury to the arterial
wall results in migration, proliferation, and deposition of
extracellular matrix material by SMCs, leading to intimal
hyperplasia.1-3 This neointimal SMC proliferative response
contributes to the pathogenesis of several cardiovascular
disorders, including atherosclerosis.4 Neointimal hyperpla-
sia is not only a major cause of early restenosis after inter-
vention in the cardiovascular system but is associated with
hemodynamically significant restenosis at the endarterec-
tomy site in patients undergoing carotid endarterectomy
and is a major factor in graft failure in the coronary and
peripheral arterial systems.5,6 Many growth factors influ-
ence proliferation of vascular SMCs in vitro and in vivo,7-10
but a clear understanding of this process is needed to design
strategies for prevention and treatment.
Endogenous opioid peptides are potent regulators of
growth11-16 and neuromodulators17 and may participate in
pial artery dilation.18 One native opioid peptide, [Met5]-
enkephalin, encoded by the preproenkephalin gene, is a
negative growth regulator in development, cellular re-
newal, wound healing, cancer, and angiogenesis.12 To dis-
tinguish the role of [Met5-enkephalin as a growth factor in
neural and nonneural cells and tissues and in prokaryotes
and eukaryotes, this peptide was termed opioid growth
factor (OGF).12 This endogenous opioid peptide is a con-
stitutively active, autocrine expressed, and secreted inhibi-
tory growth factor with broad action and function. OGF
displays activity at physiologically relevant concentrations,
and it does not elicit physical dependence, tolerance, or
withdrawal. This peptide has a direct, rapid, prolonged,
stereospecific, receptor-mediated, noncytotoxic, reversible
influence on growth in vitro and in prokaryotic and eukary-
otic organisms. At least three biological processes, ie, cell
proliferation, cell migration, and tissue organization, are
associated with OGF activity. Blockade of the interaction of
OGF with its receptor, OGFr, with antibody neutraliza-
tion, opioid antagonist (naltrexone [NTX]), or antisense
technology enhances cell replication, migration, and orga-
nizational cues, suggesting that OGF is tonically active.
OGFr has been cloned and sequenced, and human OGFr
has a chromosomal location at 20q13.3.12 Although OGF
has receptor-mediated action that is pharmacologically sim-
ilar to characteristics of an opioid receptor (eg, naloxone
[NAL] reversible, stereospecificity), the receptor has no
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homology to classical opioid receptors but is distinctly
different in structure.12
Gene and protein expression for OGF have been doc-
umented in endothelial cells, smooth muscle cells, and
fibroblasts in the neonatal and adult rat aorta,13,14 and this
autocrine-produced peptide inhibits DNA synthesis in the
newborn rat aorta.14 Moreover, OGF is a tonically active
negative growth regulator in measures of angiogenesis15,16
and has a differential effect on arteries and veins.16 The
question can be raised as to whether endogenous opioids,
specifically OGF, have a role in wound repair of vasculature.
Using the well-documented balloon catheterization model
of the common carotid artery in the rat,3 and recognizing
the limitations of this model,3 the effects of excess agonist
(OGF) and continuous blockade of opioid-receptor inter-
actions (NTX) during remodeling on DNA synthesis were
evaluated. Receptor mediation of OGF action also was
evaluated during healing of injured carotid artery. The
influence of OGF and NTX on cross-sectional morphomet-
ric analysis of intimal area, ratio of intima-media area, and
percent luminal narrowing were examined. Finally, to as-
certain the presence of OGF and OGFr in the carotid
artery, immunohistochemistry was used.
METHODS
Animals and surgery. The arterial injury model used
in this study followed the technique of Clowes et al.19,20
Adult male Sprague-Dawley AVF rats, weighing 350 to
450 g, were obtained from Charles River Laboratories
(Wilmington, Mass). Rats were anesthetized with intraperi-
toneal injection of xylazine (10 mg/kg) and ketamine (50
mg/kg), and the common, internal, and external carotid
arteries were exposed bilaterally through a midline neck
incision. Arteriotomy was performed in the left external
carotid artery to introduce a 2F Fogarty balloon catheter
into the common carotid artery and advance it to the aortic
arch. The balloon was inflated and passed three times with
gentle resistance along the length of the carotid artery to
denude the endothelium and injure the innermost layers of
the medial smooth muscle of the common carotid artery.
The balloon catheter was removed and the external carotid
artery was ligated.
Drug treatment. Immediately after balloon angio-
plasty, rats were randomly assigned to groups receiving
daily (9:00-10:00 AM) intraperitoneal injections of [Met5]-
enkephalin (OGF, 10 mg/kg), OGF (10 mg/kg) and NAL
(20 mg/kg), NAL (20 mg/kg), NTX (30 mg/kg), or an
equivalent volume of sterile water (control). A dose of 10
mg/kg of OGF markedly depresses DNA synthesis in de-
veloping vascular cells.14 Although the pharmacokinetics of
this dosage of OGF are not known, a study21 monitoring
OGF with high-pressure liquid chromatography in rats
showed that injections of 40 mg/kg of OGF into adult rats
persisted for at least 14 hours. Extrapolation to a dosage of
10 mg/kg OGF could suggest that this peptide is present
for at least 3 to 4 hours. NTX at 30 mg/kg was selected
because this dose blocks morphine-induced anti-nocicep-
tion for at least 24 hours.22 A dose of 10 mg/kg of the
short-acting (effective duration of action, 1 hour) and low-
potency opioid antagonist NAL was used because it blocks
the effects of OGF without having any influence on vascular
growth (eg, DNA synthesis) when administered alone.14
Autoradiography. At least 6 rats from each treatment
group were examined at 1, 2, 4, 7, 14, and 28 days after
surgery. On the day of collection, rats were injected with
[3H]-thymidine (0.5 mCi per rat per injection; 20 Ci/
mmol, New England Nuclear, Boston, Mass) every hour
for 3 hours (three injections, for a total of 1.5 mCi).
Animals were anesthetized with 0.9 mL of sodium pento-
barbital, and 10% neutral buffered formalin solution was
perfused through the left ventricle at 120 mm Hg of
pressure. Arteries were removed and fixed with immersion
in buffered formalin solution for 18 hours. The specimens
were embedded in paraffin, and sections (8 m in cross
section) were processed for autoradiography. After a 14-
day incubation at 4° C, the tissues were developed and
counterstained with hematoxylin-eosin.
Labeling indexes. With sections taken from the cen-
ter of the injured segment, at least 300 cells were counted in
each section from five sections per rat (six rats per group per
time point). The labeling index was determined as the ratio
of labeled cells to total number of cells; only cells with
nuclei in the intima and media were counted. Labeled cells
were those cells with four or more grains (background was
less than or equal to one grain per cell).
Morphometric analysis. Images of the cross sections
of the carotid arteries were captured with a Sony CCD
camera attached to an Olympus BH-2 microscope with
Adobe Photoshop 4.0. The thickness of the intima and of
the media were measured independently with Optimas 6.0
software according to previous methods.8,23-25 For each
section, four random noncontiguous microscopic fields
were examined, and the mean thickness of the intima and
media were determined; at least two nonadjacent sections
per carotid artery, six rats per group per time point were
used. The ratio of the thickness of intima to thickness of
media was calculated at each age to control for the plane of
section, interanimal variation, and variation in arteries.
On day 14 after de-endothelialization, the areas of the
intima and media were measured in two sections per ani-
mal, and 3 animals per group, with the Optimas program.
Medial area was calculated by subtracting the area defined
by the internal elastic lamina from the area defined by the
external elastic lamina, and intimal area was determined as
the area defined by the luminal surface and the internal
elastic lamina.8 In addition, the ratio of area of intima to
area of media was calculated.
Luminal opening. To determine whether the vessel
size had changed because of alterations in the outer wall
rather than the lumen, area and perimeter measurements of
the inside and outside dimensions of vessels were taken
from cross sections of the wounded arteries at 14 and 28
days after surgery with at least two nonadjacent sections per
carotid artery, six rats per group.
Immunohistochemistry. To examine the localization
of OGF and OGFr in carotid arteries, fresh tissue was
JOURNAL OF VASCULAR SURGERY
Volume 37, Number 3 Zagon et al 637
harvested from naive rats and immunohistochemical proce-
dures were performed as described.14 Tissues were incu-
bated for 16 to 18 hours at 4° C with primary antibodies
(1:100) to either OGF (CO-172) or OGFr (AO-440);
characterization of each polyclonal antibody has been pub-
lished.14 Secondary antibodies were rhodamine-conju-
gated goat anti-rabbit immunoglobulin G (1:100). Con-
trol sections were those stained with antibodies
preabsorbed with an excess of the respective antigen and
sections stained with only secondary antibody.
To identify SMCs and to examine for the presence of
endothelial cells, carotid arteries at 14 days after balloon
catheterization and daily injection of OGF, NTX, or sterile
water were stained with a monoclonal mouse anti-human
smooth muscle actin antibody (clone 1A4) or rabbit anti-
human von Willebrand factor (DAKO Corp, Carpinteria,
Calif).
Statistics. All experiments were performed by investi-
gators blinded to the data. Data on labeling indexes and
morphometric analysis were compared within each time
point with one-way analysis of variance, and subsequent
comparisons were made with Newman-Keuls multiple
comparisons tests (GraphPad Prism, San Diego, Calif).
RESULTS
DNA synthesis. The role of endogenous opioids on
DNA synthesis after balloon angioplasty was examined over
28 days. Labeling indexes in the intima and media from
animals injected over the long term with either OGF or
NTX are presented in Fig 1. On days 1 and 2 after surgery
there was no appearance of an intima at the light micro-
scopic level of resolution. At 4 days after injury and for at
least an additional 10 days, prolonged NTX treatment
elevated DNA synthesis by 35% to 62% from control levels.
OGF had a profound effect of depressing DNA synthesis,
with decrease from control values of 78% at 4 days, 60% at 7
days, and 32% at 14 days after injury. At 4 weeks after
balloon catheterization, labeling index in the carotid artery
was at baseline value (1.40% 0.02%) for all groups of rats.
Changes in DNA synthesis in the media of the carotid
artery of animals subjected to denuding of the endothelium
were recorded within 1 day of injury. In NTX-treated
animals, the number of cells incorporating radioactive thy-
midine increased, ranging from 21% to 89% over control
levels. In animals receiving OGF, labeling index was de-
creased, ranging from 16% to 67% of control values during
the first 2 weeks after injury. At 4 weeks after injury,
Fig 1. Histograms of labeling indexes in intima and media of carotid arteries after injury. Adult male rats received daily
injections of NTX (30 mg/kg), OGF (10 mg/kg), or equivalent volume of sterile water (control) beginning at the time
of injury. Data represent mean SEM for five sections per animal, six animals per group; at least 300 cells were counted
for each section. Dotted line, Baseline cell turnover in an uninjured rat carotid artery. *P .05; **P .01; ***P .001.
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labeling index in all groups was comparable with control
values (less than 1%). The opioid antagonist NTX signifi-
cantly increased thymidine incorporation within 24 hours
of surgery, with NTX-treated rats having 89% more cells
undergoing DNA synthesis than control counterparts. The
NTX group had a significantly higher labeling index than
did the control group through the first week after injury,
ranging from 21% to 89% greater. At 1 month after balloon
catheterization, the level of DNA synthesis in the media was
comparable between the control group and NTX-treated
rats.
Receptor mediation. To inquire whether the effects
of OGF on DNA synthesis in the injured carotid artery were
receptor mediated in the intima and media, specimens at 4
days after injury from animals receiving OGF, OGF and the
short-acting opioid antagonist NAL, and NAL alone were
examined (Fig 2). OGF inhibited DNA synthesis in the
intima and media by 78% and 16%, respectively, from
control values, whereas neither OGF and NAL nor NAL
alone had any effect on labeling index.
Morphometric analysis. The structural repercussions
of treatment with OGF and NTX on the carotid artery after
balloon catheterization were analyzed at days 4, 7, 14, and
28 after injury (Figs 3 to 5). Gross changes in the thickness
of the media were not noted between groups, but the
intima of the OGF-exposed group was subnormal by 31%
at 7 days , 26% at 14 days, and 18% at 28 days. The thickness
of the intima of the NTX-treated group was increased from
control levels by 31% at 7 days, 25% at 14 days, and 10% at
28 days. The ratio of intima thickness to media thickness in
the repairing carotid artery in rats subjected to OGF was
subnormal, by 25% at 7 days, 20% at 14 days, and 15% at 28
days (Fig 3). The ratio of intima to media thickness in the
carotid artery of rats treated with NTX was elevated from
control values, by 28% at 7 days, 16% at 14 days, and 11% at
28 days after injury (Fig 3). Results of immunohistochem-
istry revealed that the neointima in the OGF, NTX, and
control groups at 14 days after injury stained with antibod-
ies to smooth muscle actin (data not shown), arguing that
the cells of the media, not the adventitial elements, make a
major contribution to vascular remodeling. The luminal
border of the wounded carotid artery was not composed of
cells stained with von Willebrand factor, suggesting that
these neointimal cells were derived from the SMCs.3
At 14 days after wounding of the carotid artery, calcu-
lation of the ratio of intima-media area showed a 79%
reduction from control values (2.6  0.2) for the OGF
group and a 62% increase in the NTX-treated specimens;
these differences were statistically significant (P  .01).
At the conclusion of the experiments 1 month after
injury, the area and circumference of the lumen in the OGF
group were increased 23% and 28%, respectively, from
control levels (Fig 4). The NTX group had a significantly
smaller lumen compared with the control group in area and
circumference, with reductions of 17% and 4%, respectively.
Expression of OGF and OGFr. Assessment of OGF
and OGFr expression in the carotid artery showed that both
peptide and receptor had a similar pattern of immunoreac-
tivity in the carotid artery (Fig 6). The cytoplasm of endo-
thelial, smooth muscle, and fibroblast cells was immunore-
active, and staining extended into the cell processes (Fig 6,
A, C). Little immunoreactivity was recorded in the nuclei of
these cell types. No staining was detected in control speci-
mens processed with antibody preabsorbed with respective
antigens or in samples incubated with secondary antibody
only (Fig 6, B, D).
DISCUSSION
Modulation of a native opioid-receptor system has a
profound effect on cell replication after injury of an artery.
In a well-documented model of arterial wounding,3,19,20
application of exogenous OGF depressed DNA synthesis
during the course of healing, suggesting that endogenous
OGF (as shown at immunohistochemistry to be present in
these carotid arteries) acted as a negative growth regulator,
a function of OGF reported earlier in the homeostasis of
cellular renewal of neonatal rat aorta.14 OGF had a recep-
Fig 2. Histograms of labeling indexes in intima and media of
carotid arteries 4 days after injury. Adult male rats received daily
injections of OGF, 10 mg/kg; OGF, 10 mg/kg, and NAL, 20
mg/kg; NAL alone, 20 mg/kg; or equivalent volume of sterile
water (control). Data represent mean  SEM for five sections per
animal, six animals per group; at least 300 cells were counted for
each section. *P  .05; ***P  .001.
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Fig 4. Area and circumference of lumen of carotid artery at 28 days after injury. Animals received daily injections of
NTX, 30 mg/kg; OGF, 10 mg/kg; or equivalent volume of sterile water (control) beginning at the time of injury. Data
represent mean  SEM of measurements from five sections per animal, six animals per group. ***P  .001.
Fig 3. Ratio of intima to media thickness in carotid artery after injury. Animals received daily injections of NTX, 30
mg/kg; OGF, 10 mg/kg; or equivalent volume of sterile water (control) beginning at the time of injury. Data represent
mean  SEM for five sections per animal, six animals per group. *P  .05; **P  .01.
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tor-mediated effect on DNA synthesis in the carotid artery
subjected to denudation of the endothelium, because the
low-potency, short-acting opioid antagonist NAL neutral-
ized OGF when given concomitantly, but NAL given once
at this dosage alone had no effect. This finding was conso-
nant with the observation of OGFr in the carotid artery at
immunohistochemistry. Exposure of the injured carotid
artery to the potent, long-acting opioid antagonist NTX
with a dosage that blocks opioid-receptor interaction11
increased DNA synthesis levels; since the duration of opi-
oid-receptor blockade rather than dosage is a determinant
of opioid-induced modulation of growth,22 other opioid
antagonists (eg, NAL) would be expected to have a similar
effect, given the appropriate conditions. Although NTX
blocks classical (, , ) and nonclassical (OGFr) receptors,
only OGF is related to cell replication.14 Therefore OGF
must be a tonically active and constitutively expressed
growth factor, because displacement of OGF from the
cellular elements in the injured intima and media undergo-
ing DNA synthesis by NTX resulted in increased cell repli-
cation. Thus, although the native opioid peptide OGF has
a role in vasculogenesis, angiogenesis, and homeostatic
cellular renewal of blood vessels, and does so at the locus of
OGFr,14-16 we now see for the first time that the OGF-
OGFr axis is important in regulation of DNA synthesis for
repair of injured vasculature.
The total effect that the OGF-OGFr axis exerts on cell
replication is sizable. The activity of endogenous OGF on
cell replication can be estimated by summation of the
effects of opioid-receptor blockade with NTX and those of
exogenously administered OGF. Specifically, an increase in
radioactive thymidine incorporation in only 3 hours ranged
from 35% to 62% in the intima during the first 2 weeks after
injury, and from 21% to 89% in the media over the same
period. The capacity of exogenous OGF, presumably acting
by saturating sites where endogenous peptide is absent,
must be given consideration. Exposure to OGF decreased
DNA synthesis by 32% to 78% in the intima and by 16% to
Fig 5. Photomicrographs of cross sections through rat carotid artery 14 days after balloon angioplasty. Animals
received daily injections of sterile water in equivalent volume to OGF or NTX (control; A and B); OGF, 10 mg/kg (C
and D); or NTX, 30 mg/kg (E and F) beginning at the time of injury. Sections were stained with hematoxylin-eosin.
ADV, Adventitia; MED, media; NEO, neointima; LU, lumen. Bar, A, C, E, 1.8 mm; B, D, F, 0.6 mm.
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67% in the media during the first 2 weeks after balloon
catheterization. Thus summing the effects of endogenous
and exogenous OGF activity yields a cumulative effect on
growth as great as 146% in the injured intima and media
within 3 hours of [3H]-thymidine administration. These
calculations confirm that the OGF-OGFr axis has a pro-
found and important regulatory effect in governing the
equilibrium of cellular duplication after de-endothelializa-
tion. Given that we may only be looking at a daily 3-hour to
4-hour window of OGF exposure estimated from previous
information,21 more extended exposure and elimination of
intermittent repercussions from OGF treatment could yield
even greater changes. Thus an abundance or deficiency in
OGF could have dramatic consequences on DNA synthesis
of cells in the blood vessel during repair.
Alterations in DNA synthesis induced with manipula-
tion of OGF-OGFr interfacing were manifested in changes
in the magnitude of wound healing of the carotid artery. In
OGF-treated animals the area of the lumen was approxi-
mately 25% larger than in the control group within 1 month
of injury. This increase in area of the lumen of the carotid
artery in animals subjected to OGF beginning at the time of
balloon catheterization was due to reduction in the thick-
ness and area of the intima as a result of cumulative reduc-
tion in cell proliferation and possibly diminishment in
differentiation processes in the reestablished intima. Thus
exposure to OGF in the process of wound repair of this
artery diminished cell replication without altering luminal
dimensions, suggesting enhancement of hemodynamic
processes. In the case of animals in which OGF-OGFr
interactions were continuously blocked by the opioid an-
tagonist NTX, the area of the lumen was decreased by 17%.
This reduction in luminal area was the result of notable
increases in neointimal wall thickness and area. These data
indicate that disruption of OGF-OGFr interaction can
exacerbate events related to neointimal proliferation and
lead to diminished luminal size, thereby restricting blood
flow. At least four distinct processes contribute to resteno-
sis: proliferation of SMCs, migration of SMCs from the
vessel media to the intima, deposition of extracellular ma-
trix material by SMCs, and contraction of neointimal tissue
by SMCs.19,20,26-28 With application of this knowledge to
OGF modulation of blood vessel repair, our studies clearly
demonstrate that the OGF-OGFr axis has a profound in-
fluence on DNA synthesis of cells positive for smooth
muscle actin, putative SMCs. We found the temporal se-
quence of an increase in cell replication in the media
preceding that in the intima was consistent with the results
of other investigators.3,19 Moreover, OGF-OGFr interac-
tions can now be seen to affect cell replication in both the
media (giving rise to cells feeding the intima) and the
intima, and to do so in a manner consonant with the
timetable of migration and cellular repopulation. Only the
magnitude of DNA synthesis in the media and intima of rats
treated with OGF or NTX deviated from control levels.
These results infer that cell proliferation is a prime target for
OGF activity in regard to blood vessel repair. Although cell
migration in the corneal epithelium is influenced by
OGF,29 it remains to be seen whether cell migration from
media to intima in the injured artery is also affected by the
OGF-OGFr axis. From studies in other cells and tissues, it
is known that OGF is not cytotoxic29 and does not involve
necrotic or apoptotic pathways.30 In fact, OGF appears to
be a cytostatic agent and to act on the cell cycle by prolong-
ing the G0/G1 phase.
31 NTX increases the number of cells
in DNA synthesis by shortening the timetable of the cell
cycle, particularly the G0/G1 phase and recruitment of cells
into the S phase, but does not alter survival time.31 Thus
OGF appears to be a tonically active inhibitory growth
factor that is targeted to cell proliferative events and does
not decrease cells through cytotoxicity. To date, many
growth factors have been reported to also act through
proliferative pathways, but many stimulate vascular smooth
muscle proliferation (eg, IGF-1, acidic-fibroblast growth
factor, basic-fibroblast growth factor, platelet-derived
growth factor).3,32 However, only a few (eg, heparin, reti-
noblastoma protein) inhibit vascular proliferation,33,34 and
the mechanisms of these compounds need to be ascertained
before comparisons and relationships can be drawn to
OGF.
Our data extend knowledge that the OGF-OGFr axis is
important in vasculogenesis and angiogenesis,14-16 but ma-
nipulation of this system in the course of vessel repair may
have dramatic consequences on vessel architecture that will
ultimately contribute to enhancing circulatory properties.
Fig 6. Photomicrographs of immunohistochemical preparations
of cross sections through uninjured carotid artery. Preparations
were stained with antibodies to OGF (A and B) or OGFr (C and
D), with immunoreactivity denoted by arrow. Control sections
were stained with antibodies preabsorbed with pure antigens (B
and D). LU, Lumen; INT, intima; MED, media; ADV, adventitia.
Bar, 0.5 mm.
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It appears that the inhibitory capabilities of the autocrine
loop involved with OGF-OGFr interfacing on cell prolifer-
ation is disrupted by injury and that sufficient OGF cannot
be made available to maintain equilibrium for cell replica-
tion. Although animal paradigms such as the rat carotid
injury model have limitations, eg, lack of atherosclerotic
plaque, they do offer insight into the pathophysiologic
mechanisms of intimal hyperplasia.3 Thus OGF treatment
to restore negative regulation may be of therapeutic benefit
in such circumstances. Further studies are needed.
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